Enzo Biochem EBITDA Margin 2010-2023 | ENZ
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Enzo Biochem (ENZ) over the last 10 years. The current EBITDA margin for Enzo Biochem as of January 31, 2023 is .
| Enzo Biochem EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-01-31 |
$0.08B |
$-0.03B |
-37.50% |
| 2022-10-31 |
$0.10B |
$-0.02B |
-19.39% |
| 2022-07-31 |
$0.11B |
$-0.01B |
-10.28% |
| 2022-04-30 |
$0.11B |
$-0.01B |
-6.25% |
| 2022-01-31 |
$0.12B |
$-0.00B |
-1.68% |
| 2021-10-31 |
$0.12B |
$0.00B |
0.86% |
| 2021-07-31 |
$0.12B |
$0.00B |
2.54% |
| 2021-04-30 |
$0.11B |
$0.00B |
1.77% |
| 2021-01-31 |
$0.10B |
$-0.01B |
-10.31% |
| 2020-10-31 |
$0.09B |
$-0.02B |
-22.35% |
| 2020-07-31 |
$0.08B |
$-0.03B |
-35.53% |
| 2020-04-30 |
$0.08B |
$-0.03B |
-36.36% |
| 2020-01-31 |
$0.08B |
$0.00B |
5.00% |
| 2019-10-31 |
$0.08B |
$0.00B |
3.75% |
| 2019-07-31 |
$0.08B |
$0.00B |
6.17% |
| 2019-04-30 |
$0.08B |
$0.00B |
6.02% |
| 2019-01-31 |
$0.09B |
$-0.02B |
-22.73% |
| 2018-10-31 |
$0.10B |
$-0.01B |
-14.74% |
| 2018-07-31 |
$0.10B |
$-0.01B |
-8.91% |
| 2018-04-30 |
$0.10B |
$-0.00B |
-3.88% |
| 2018-01-31 |
$0.11B |
$-0.00B |
-0.95% |
| 2017-10-31 |
$0.11B |
$0.00B |
0.95% |
| 2017-07-31 |
$0.10B |
$0.00B |
0.96% |
| 2017-04-30 |
$0.11B |
$0.04B |
36.79% |
| 2017-01-31 |
$0.11B |
$0.04B |
34.29% |
| 2016-10-31 |
$0.10B |
$0.04B |
42.31% |
| 2016-07-31 |
$0.10B |
$0.05B |
48.54% |
| 2016-04-30 |
$0.10B |
$0.02B |
21.57% |
| 2016-01-31 |
$0.10B |
$0.02B |
22.00% |
| 2015-10-31 |
$0.10B |
$0.01B |
11.22% |
| 2015-07-31 |
$0.10B |
$0.00B |
3.06% |
| 2015-04-30 |
$0.10B |
$-0.01B |
-9.28% |
| 2015-01-31 |
$0.10B |
$-0.01B |
-7.22% |
| 2014-10-31 |
$0.10B |
$-0.01B |
-7.22% |
| 2014-07-31 |
$0.10B |
$-0.01B |
-7.29% |
| 2014-04-30 |
$0.09B |
$-0.01B |
-7.45% |
| 2014-01-31 |
$0.09B |
$-0.01B |
-11.83% |
| 2013-10-31 |
$0.09B |
$-0.01B |
-14.13% |
| 2013-07-31 |
$0.09B |
$-0.01B |
-14.89% |
| 2013-04-30 |
$0.10B |
$-0.04B |
-41.24% |
| 2013-01-31 |
$0.10B |
$-0.04B |
-38.00% |
| 2012-10-31 |
$0.10B |
$-0.04B |
-34.95% |
| 2012-07-31 |
$0.10B |
$-0.04B |
-34.95% |
| 2012-04-30 |
$0.10B |
$-0.01B |
-10.58% |
| 2012-01-31 |
$0.10B |
$-0.01B |
-9.62% |
| 2011-10-31 |
$0.10B |
$-0.01B |
-10.68% |
| 2011-07-31 |
$0.10B |
$-0.01B |
-7.77% |
| 2011-04-30 |
$0.10B |
$-0.01B |
-9.90% |
| 2011-01-31 |
$0.10B |
$-0.01B |
-12.12% |
| 2010-10-31 |
$0.10B |
$-0.02B |
-17.35% |
| 2010-07-31 |
$0.10B |
$-0.02B |
-18.56% |
| 2010-04-30 |
$0.10B |
$-0.02B |
-17.53% |
| 2010-01-31 |
$0.10B |
$-0.02B |
-17.71% |
| 2009-10-31 |
$0.09B |
$-0.02B |
-15.96% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.121B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
